Allergy Therapeutics: Grant of options
Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, pursuant to the Company’s Long Term Incentive Plan (“LTIP”) the following conditional awards of shares of 0.1 pence each were made to Executive Directors at nominal cost of 0.1 pence each on 30 December 2016.
Number of Conditional shares awarded – 1,690,000
Total conditional shares held under LTIPs – 3,380,000
Number of Conditional shares awarded – 422,500
Total conditional shares held under LTIPs – 422,500
The issuance and distribution of ordinary shares of 0.1 pence each under the LTIP is conditional on the satisfaction of performance conditions which include an earnings growth test over a three year testing period to 30 June 2019 and share price growth over the 3 year plan cycle.
Allergy Therapeutics Investors Video